Real world outcomes of photodynamic therapy for chronic central serous chorioretinopathy
Authors:
Open Access
- 26 December 2022
- journal article
- research article
- Published by Springer Nature in Eye
- Vol. 37 (12) , 2548-2553
Abstract
Objectives: We describe the real-world outcomes of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSCR) in a single centre over nine years. Methods: We carried out a retrospective analysis of patients with chronic CSCR who received half dose PDT in a single centre between 2011 and 2019. Visual acuity (VA) and retinal thickness (RT) was recorded between baseline visit and first recorded review visit. Results: We included 125 eyes of 113 patients in this study. Mean age at treatment was 55.0 ± 12.1 years, with a higher male predominance (83 men, 30 women). Mean baseline VA was 0.40 ± 0.31 logMAR with a mean visual outcome gain post-PDT of 0.05 logMAR (p = 0.005). Mean baseline RT was 390 ± 82 microns with a mean reduction of RT post-PDT of 66 microns (p < 0.001). 17.6% of eyes were treated for recurrent CSCR. Conclusion: We found overall a mean improvement in VA and structural outcomes after PDT. In the absence of randomised clinical trials this study supports the use of half dose PDT for treatment of chronic CSCR.Keywords
This publication has 17 references indexed in Scilit:
- Central serous chorioretinopathy: Towards an evidence-based treatment guidelineProgress in Retinal and Eye Research, 2019
- Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous ChorioretinopathyOphthalmology, 2018
- Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathyClinical Ophthalmology, 2017
- Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up studyPLOS ONE, 2017
- A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous ChorioretinopathyAmerican Journal of Ophthalmology, 2016
- One-Year Outcomes with Half-Dose Verteporfin Photodynamic Therapy for Chronic Central Serous ChorioretinopathyOphthalmology, 2015
- Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).2015
- Reproducibility of Retinal Thickness Measurements on Normal and Pathologic Eyes by Different Optical Coherence Tomography InstrumentsAmerican Journal of Ophthalmology, 2010
- SAFETY ENHANCED PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHYRetina, 2008
- Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.2001